Neuroendocrinological function in Alzheimer's disease

M. Franceschi, L. Perego, L. Ferini-Strambi, S. Smirne, N. Canal

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The neuroendocrine function is regulated by several neurotransmitters (acetylcholine, dopamine, somatostatin and noradrenaline) known to be reduced in brains of patients with Alzheimer's disease (AD). Moreover, the hypothalamus also has pathological changes. In spite of these findings suggesting neuroendocrine dysfunctions, this function has seldom been investigated in AD patients so far. We have compared patients with clinically 'probable' AD of mild-to-moderate severity with nondemented age- and sex-matched controls. Plasma levels of prolactin (PRL), growth hormone (GH) and thyroid-stimulating hormone (TSH) were measured by commercially available radioimmunoassays (RIA) before and after stimulation with metoclopramide, l-dopa or thyrotropin-releasing hormone. Basal plasma levels of β-endorphin and β-lipotropin were measured by RIA after high-performance liquid chromatography. Basal and stimulated plasma levels of PRL, GH, TSH and β-lipotropin were similar in the two groups. Basal plasma levels of β-endorphin were significantly higher in the patient group. Of doubtful clinical importance, this might be attributed to decreased tuberoinfundibular dopaminergic activity and has also been seen in patients with Parkinson's disease.

Original languageEnglish
Pages (from-to)367-370
Number of pages4
JournalNeuroendocrinology
Volume48
Issue number4
Publication statusPublished - 1988

Fingerprint

Alzheimer Disease
beta-Lipotropin
Endorphins
Thyrotropin
Prolactin
Growth Hormone
Radioimmunoassay
Dihydroxyphenylalanine
Metoclopramide
Thyrotropin-Releasing Hormone
Somatostatin
Hypothalamus
Acetylcholine
Neurotransmitter Agents
Parkinson Disease
Dopamine
Norepinephrine
High Pressure Liquid Chromatography
Brain

ASJC Scopus subject areas

  • Endocrinology
  • Neuroscience(all)

Cite this

Franceschi, M., Perego, L., Ferini-Strambi, L., Smirne, S., & Canal, N. (1988). Neuroendocrinological function in Alzheimer's disease. Neuroendocrinology, 48(4), 367-370.

Neuroendocrinological function in Alzheimer's disease. / Franceschi, M.; Perego, L.; Ferini-Strambi, L.; Smirne, S.; Canal, N.

In: Neuroendocrinology, Vol. 48, No. 4, 1988, p. 367-370.

Research output: Contribution to journalArticle

Franceschi, M, Perego, L, Ferini-Strambi, L, Smirne, S & Canal, N 1988, 'Neuroendocrinological function in Alzheimer's disease', Neuroendocrinology, vol. 48, no. 4, pp. 367-370.
Franceschi M, Perego L, Ferini-Strambi L, Smirne S, Canal N. Neuroendocrinological function in Alzheimer's disease. Neuroendocrinology. 1988;48(4):367-370.
Franceschi, M. ; Perego, L. ; Ferini-Strambi, L. ; Smirne, S. ; Canal, N. / Neuroendocrinological function in Alzheimer's disease. In: Neuroendocrinology. 1988 ; Vol. 48, No. 4. pp. 367-370.
@article{118023df61af43f8b232b6eb6b222ad5,
title = "Neuroendocrinological function in Alzheimer's disease",
abstract = "The neuroendocrine function is regulated by several neurotransmitters (acetylcholine, dopamine, somatostatin and noradrenaline) known to be reduced in brains of patients with Alzheimer's disease (AD). Moreover, the hypothalamus also has pathological changes. In spite of these findings suggesting neuroendocrine dysfunctions, this function has seldom been investigated in AD patients so far. We have compared patients with clinically 'probable' AD of mild-to-moderate severity with nondemented age- and sex-matched controls. Plasma levels of prolactin (PRL), growth hormone (GH) and thyroid-stimulating hormone (TSH) were measured by commercially available radioimmunoassays (RIA) before and after stimulation with metoclopramide, l-dopa or thyrotropin-releasing hormone. Basal plasma levels of β-endorphin and β-lipotropin were measured by RIA after high-performance liquid chromatography. Basal and stimulated plasma levels of PRL, GH, TSH and β-lipotropin were similar in the two groups. Basal plasma levels of β-endorphin were significantly higher in the patient group. Of doubtful clinical importance, this might be attributed to decreased tuberoinfundibular dopaminergic activity and has also been seen in patients with Parkinson's disease.",
author = "M. Franceschi and L. Perego and L. Ferini-Strambi and S. Smirne and N. Canal",
year = "1988",
language = "English",
volume = "48",
pages = "367--370",
journal = "Neuroendocrinology",
issn = "0028-3835",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Neuroendocrinological function in Alzheimer's disease

AU - Franceschi, M.

AU - Perego, L.

AU - Ferini-Strambi, L.

AU - Smirne, S.

AU - Canal, N.

PY - 1988

Y1 - 1988

N2 - The neuroendocrine function is regulated by several neurotransmitters (acetylcholine, dopamine, somatostatin and noradrenaline) known to be reduced in brains of patients with Alzheimer's disease (AD). Moreover, the hypothalamus also has pathological changes. In spite of these findings suggesting neuroendocrine dysfunctions, this function has seldom been investigated in AD patients so far. We have compared patients with clinically 'probable' AD of mild-to-moderate severity with nondemented age- and sex-matched controls. Plasma levels of prolactin (PRL), growth hormone (GH) and thyroid-stimulating hormone (TSH) were measured by commercially available radioimmunoassays (RIA) before and after stimulation with metoclopramide, l-dopa or thyrotropin-releasing hormone. Basal plasma levels of β-endorphin and β-lipotropin were measured by RIA after high-performance liquid chromatography. Basal and stimulated plasma levels of PRL, GH, TSH and β-lipotropin were similar in the two groups. Basal plasma levels of β-endorphin were significantly higher in the patient group. Of doubtful clinical importance, this might be attributed to decreased tuberoinfundibular dopaminergic activity and has also been seen in patients with Parkinson's disease.

AB - The neuroendocrine function is regulated by several neurotransmitters (acetylcholine, dopamine, somatostatin and noradrenaline) known to be reduced in brains of patients with Alzheimer's disease (AD). Moreover, the hypothalamus also has pathological changes. In spite of these findings suggesting neuroendocrine dysfunctions, this function has seldom been investigated in AD patients so far. We have compared patients with clinically 'probable' AD of mild-to-moderate severity with nondemented age- and sex-matched controls. Plasma levels of prolactin (PRL), growth hormone (GH) and thyroid-stimulating hormone (TSH) were measured by commercially available radioimmunoassays (RIA) before and after stimulation with metoclopramide, l-dopa or thyrotropin-releasing hormone. Basal plasma levels of β-endorphin and β-lipotropin were measured by RIA after high-performance liquid chromatography. Basal and stimulated plasma levels of PRL, GH, TSH and β-lipotropin were similar in the two groups. Basal plasma levels of β-endorphin were significantly higher in the patient group. Of doubtful clinical importance, this might be attributed to decreased tuberoinfundibular dopaminergic activity and has also been seen in patients with Parkinson's disease.

UR - http://www.scopus.com/inward/record.url?scp=0023695373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023695373&partnerID=8YFLogxK

M3 - Article

C2 - 2974929

AN - SCOPUS:0023695373

VL - 48

SP - 367

EP - 370

JO - Neuroendocrinology

JF - Neuroendocrinology

SN - 0028-3835

IS - 4

ER -